The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://youtu.be/LxBgm9hiEEY
Open Orphan from 1.33.50
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly traded shares outstanding upon listing, excluding those held by officers, directors, or any beneficial owners of more than 10% of the company.
The regular bid price of shares of the company's stock at the time of listing must be at least $4.00. However, a company may qualify under a closing price alternative of $3.00 or $2.00 if the company meets varying requirements.
There must be at least three (or four depending on the criteria) market makers for the stock. For companies using the $3 or $2 criteria, only two market makers may be required. Each listing firm is also required to follow NASDAQ corporate governance rules 4350, 4351, and 4360.
Companies must also have at least 450 round lot (i.e., 100 shares or more) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.
As of 2020, a company must pay a $25,000 application fee before its stock can even be considered for listing, and it can expect to pay between $150,000 and $295,000 in entry fees if successful.
In addition to these requirements, companies must meet all of the criteria under at least one of the following standards.2?
Standard No. 1: Earnings
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the previous two years at least $2.2 million, and no single year in the prior three years can have a net loss.
Standard No. 2: Capitalization With Cash Flow
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. Also, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.
Standard No. 3: Capitalization With Revenue
Companies can be removed from the cash flow requirement of the second standard if its average market capitalization over the past 12 months is at least $850 million and revenues over the prior fiscal year are at least $90 million.
Standard No. 4: Assets With Equity
Companies can eliminate the cash flow and revenue requirements, and decrease its marketing capitalization requirements to $160 million if their total assets total at least $80 million and their stockholders' equity is at least $55 million.
To stay listed on the Nasdaq, a company must continue to meet the minimum listing requirements or risk being delisted and removed from the Nasdaq exchange.
The Bottom Line
A company has four ways to get listed on the NASDAQ, depending on the underlying fundamentals of the company. If a company does not meet certain criteria, such as the operating income minimum, it has to make it up with larger minimum amounts in another area, like revenue. This helps to improve the quality of companies listed on the exchange.
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly traded shares outstanding upon listing, excluding those held by officers, directors, or any beneficial owners of more than 10% of the company.
The regular bid price of shares of the company's stock at the time of listing must be at least $4.00. However, a company may qualify under a closing price alternative of $3.00 or $2.00 if the company meets varying requirements.
There must be at least three (or four depending on the criteria) market makers for the stock. For companies using the $3 or $2 criteria, only two market makers may be required. Each listing firm is also required to follow NASDAQ corporate governance rules 4350, 4351, and 4360.
Companies must also have at least 450 round lot (i.e., 100 shares or more) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.
As of 2020, a company must pay a $25,000 application fee before its stock can even be considered for listing, and it can expect to pay between $150,000 and $295,000 in entry fees if successful.
In addition to these requirements, companies must meet all of the criteria under at least one of the following standards.2?
Standard No. 1: Earnings
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the previous two years at least $2.2 million, and no single year in the prior three years can have a net loss.
Standard No. 2: Capitalization With Cash Flow
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. Also, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.
Standard No. 3: Capitalization With Revenue
Companies can be removed from the cash flow requirement of the second standard if its average market capitalization over the past 12 months is at least $850 million and revenues over the prior fiscal year are at least $90 million.
Standard No. 4: Assets With Equity
Companies can eliminate the cash flow and revenue requirements, and decrease its marketing capitalization requirements to $160 million if their total assets total at least $80 million and their stockholders' equity is at least $55 million.
To stay listed on the Nasdaq, a company must continue to meet the minimum listing requirements or risk being delisted and removed from the Nasdaq exchange.
The Bottom Line
A company has four ways to get listed on the NASDAQ, depending on the underlying fundamentals of the company. If a company does not meet certain criteria, such as the operating income minimum, it has to make it up with larger minimum amounts in another area, like revenue. This helps to improve the quality of companies listed on the exchange.
After
He is as so much happening, would be classed as insider trading as he knows what is going on. If he is given permission then it clears him from the possible problems insider trading could bring.
Disease in Motion, during presentation mentioned up to 3 months. Very coy in questions as Codagenix is giving lots of info for wearable. Watch the space.
Next week will be give people Covid.
Influenza Immune Modulator, has been nudged along. Sounds the closest to move further.
Nothing new. He seemed a bit tired and flatish
Had to laugh as he explained how they had saved costs. 2 Pizza Rule...They are only big enough to feed 4 people so no more are needed at a meeting.(cut cost)
Just seen this on ADVFN
Cathal Friel will be presenting for Open Orphan at a Mello event tonight. We are also covering the IG Margin hike to 100% for hundreds of companies including Open Orphan and it will be in the 6pm news with a reply from IG later in the show. To register for this, please follow the link: Https://melloevents.com/mellomonday-22nd-february-2021/ Cathal will do the Open Orphan presentation at 7.25pm and there will be about 12 mins for Q&A so do have them ready to lodge in the Q&A box or alternatively you may send to Mello in advance. We have a facility for Cathal to answer all questions raised and put them on the website within 48 hours. If any of you want a half price ticket then just enter the code MMTADVFN50
Just seen this on ADVFN
Cathal Friel will be presenting for Open Orphan at a Mello event tonight. We are also covering the IG Margin hike to 100% for hundreds of companies including Open Orphan and it will be in the 6pm news with a reply from IG later in the show. To register for this, please follow the link: Https://melloevents.com/mellomonday-22nd-february-2021/ Cathal will do the Open Orphan presentation at 7.25pm and there will be about 12 mins for Q&A so do have them ready to lodge in the Q&A box or alternatively you may send to Mello in advance. We have a facility for Cathal to answer all questions raised and put them on the website within 48 hours. If any of you want a half price ticket then just enter the code MMTADVFN50
Are there any questions that are wanting to be asked by people attending Mello Monday tonight?
You need to be a member, I have obtained a Mello Virgin free ticket, as have some others. This will give me the opportunity to see if I was to become a member. 4 hours worth of investing with different companies presenting.
Healthy, young volunteers will be infected with coronavirus to test vaccines and treatments in the world's first Covid-19 "human challenge" study, which will take place in the UK.
The study, which has received ethics approval, will start in the next few weeks and recruit 90 people aged 18-30.
They will be exposed to the virus in a safe and controlled environment while medics monitor their health.
The UK has given doses of a Covid vaccine to more than 15 million people.
The Human Challenge study is being delivered by a partnership between the government's Vaccines Taskforce, Imperial College London, the Royal Free London NHS Foundation Trust and the company?hVIVO, which has pioneered viral human challenge models.
Clive Dix, interim chair of the Vaccines Taskforce, said: "We have secured a number of safe and effective vaccines for the UK, but it is essential that we continue to develop new vaccines and treatments for Covid-19.
"We expect these studies to offer unique insights into how the virus works and help us understand which promising vaccines offer the best chance of preventing the infection."
15:44:28-GMT GBX 28.4499p 1,000,000 £284499.00 OB Buy
15:44:28-GMT GBX 28.4499p 1,000,000 £284499.00 OB Buy
Scientists have identified another new variant of coronavirus in the UK with some potentially troubling mutations.
B.1.525 appears similar to the South African variant which prompted door-to-door tests in areas where it has been found.
Researchers from Edinburgh University have found 33 cases so far in samples dating back to December.
It has been seen in other countries too, including Denmark, Nigeria and the US.
UK experts are studying it to understand what risk it poses.
It is too soon to say if it should be added to the UK's list of "variants of concern" and whether mass testing for it should happen.
How does surge testing work?
South Africa variant: What is the risk?
Covid variants: What are they and will they work?
Prof Ravi Gupta, from the University of Cambridge, is one of the scientists advising the government on new and emerging virus threats.
He said B.1.525 appeared to have "significant mutations" already seen in some of the other new variants.
"That is partly reassuring because we can predict what their likely effect is."
Prof Yvonne Doyle from Public Health England (PHE) said: "PHE is monitoring data about emerging variants very closely and where necessary public health interventions are being undertaken, such as extra testing and enhanced contact tracing.
"There is currently no evidence that this set of mutations causes more severe illness or increased transmissibility."
One of these changes B.1.525 has is a mutation called E484K - also found in the Brazil and South African variants - that may help the virus evade some of the body's immune system defences.
Other alterations make it similar to the UK 'Kent' variant that experts say is more contagious than the original version of coronavirus that started the pandemic.
The concern is that the virus is changing in ways that could let it easily spread and escape from the vaccines that we already have to fight Covid.
Current ones were designed around earlier versions of coronavirus, but scientists believe they should still work against the new variants being seen now, although perhaps not quite as well.
Prof Gupta and colleagues have been running tests in the lab and say mutations like E484K do represent a threat to vaccines.
Scientists are already working on new vaccines that are a better match for new variants, in case they are needed ahead of next winter.
Thanks Bazzaman, Interesting array of companies. JLP looks quiet interesting, from I know the areas the mines are in. AS always yes I do all my own research. You seem to have a good sense of getting in early with growing companies. This is a skill I am trying to improve. Thanks again for your input.
Adz88 Thanks for your reply. I have to say your reasons are pretty similar to why I invested. I just got in later in May. And it was the Management, with no shares on offer, if you want a piece of the company then you buy your own. Picks and shovel business. Right place at the right time with regards the Covid. I have made 5 purchases in the company between May and Sept 2020. Having read a few investment books, I am just formulating my own stance on future purchases, Management, Moat, Reducing Cost, Lack of Competition, Growing Sales, seem to always be the main criteria. Thanks again for your reply.
For investors Pre April 2020, what made you invest in Open Orphan. Did you think it would be a multi bagger.
1. Was it Technical Analyse. If so what did you use?
2. Was it Fundamental Analyse. Why?
3. Did you at point of investment believe it would be a multi bagger
4. Has this method given you multi baggers before..What is the largest bagger it has give?
5. Any other reason?
I am trying to work out how people find potential multi baggers, at very early stages of a company.
RNNS after close down to 5%
Actual Study Start Date December 15, 2020.
Would this not have been when the study started and not the 05/02/2021?
With 296658000 airline passenger in 2019 even at 50p profit a test. Don't think I would sneeze at that as revenue.
Just been listening to a speaker on Master Investors. CF says 10 years of vaccine research and development. They are talking far longer and going towards a lifetime of development and research into this area. Some of the current vaccines may be showing they don't have the affecy rating we were led to believe they have. All the more work for Open Orphan and teams.